Loaded up a while back so not buying but holding and waiting this ticker out. Never have seen any negative info on mipsagargin always a prodrug with potential in many solid tumor applications. The only down side has not been concerning mipsagargin but the formulation of thapsigargin (main ingredient) as noted that it is difficult to make in commercial quantities and the current process to make it is expensive. Phyton is in the process of solving that riddle.
News 
Market Data 
Discover 
